| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025 |
| 29 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
8-K: Other Events
As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”)... |
| 01 Oct 2026 |
Form 4: Jin David, Chief Financial Officer
Received 1,190 shares as a grant or award ($2.16K) |
| 01 Sep 2026 | SCHEDULE 13G |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 |
| 24 Jun 2026 |
Form 4: Jin David, Chief Financial Officer
Received 400,000 shares as a grant or award |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | 10-Q |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million |
| 28 Apr 2026 | DEFA14A |
| 28 Apr 2026 |
Proxy statement: annual meeting on June 17, 2026
CEO pay $2.9M, up 109% |
| 01 Apr 2026 |
Form 4: Jin David, Chief Financial Officer
Received 2,967 shares as a grant or award ($6.46K) |
| 31 Mar 2026 | 10-K |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to ... |
| 30 Mar 2026 |
8-K: Other Events
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million |
| 20 Mar 2026 |
Form 4: Rosenwald Lindsay A Md, Director
Received 475,424 shares as a grant or award |
Loading...